Skip to content

Healthcare Integrity & Anti-Fraud Enforcement

§ PHX-AFK-US: Public Health Exchange Protocol for Anti-Fraud, Kickback Prevention & Secure Chain Integrity in U.S. Healthcare Facilities

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07217730
Acronym
PHX-AFK-US
Enrollment
100
Registered
2025-10-16
Start date
2025-10-13
Completion date
2034-10-13
Last updated
2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Governance Failures, Healthcare Fraud Schemes, Kickback Networks, Public Transparency & Auditability, Regulatory Escalation Pathways, Supply Chain Vulnerabilities, Validator Oversight & DAO Governance, Whistleblower Activation

Keywords

Healthcare Integrity, Anti-Fraud, Kickback Prevention, Secure Supply Chain, Validator Governance, Coalition Oversight, NFT Fiscal Instruments, Smart Contract Enforcement, DAO Voting, SHA-256 Notarization, Whistleblower Affidavits, Regulatory Escalation, Public Transparency, Audit Trail, Asset Freeze Logic, CMS / DOJ / OIG Complaints, Procurement Reform, Phantom Billing, Referral Schemes, Medical Device Provenance, Coalition Dashboard, Public Health Exchange, SOP Violations, Facility Sanctions, DeFi Escrow Logic

Brief summary

The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.

Detailed description

The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.

Interventions

OTHERValidator-Governed Reform & Regulatory Escalation Protocol

This intervention deploys a validator-governed framework to monitor, escalate, and reform healthcare facilities exhibiting fraud, kickback schemes, and supply chain vulnerabilities. It integrates notarized affidavits, smart contract enforcement, NFT fiscal declarations, and DAO voting logic to trigger sanctions, regulatory complaints, and operational restructuring. Facilities are observed prospectively, with all actions logged to a public dashboard and anchored via SHA-256 hash notarization. No biospecimens are retained; all data is legal, technical, and governance-based.

DEVICECoalition-Grade Validator Dashboard Module (CVDM-1)

The Coalition-Grade Validator Dashboard Module (CVDM-1) is a secure, web-based device deployed across enrolled healthcare facilities to enable real-time validator oversight, whistleblower affidavit intake, and smart contract enforcement. It integrates QR-linked audit trails, NFT fiscal declarations, and DAO voting logic. The device anchors all inputs via SHA-256 hash notarization and transmits reform metrics to coalition dashboards. CVDM-1 supports public transparency, regulatory escalation, and validator governance across the PHX-AFK-US Protocol. It does not collect biospecimens and operates solely within legal, technical, and governance domains.

DRUGCoalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)

The Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1) is a governance-based drug intervention targeting facilities with suspected fraud, kickback schemes, or supply chain irregularities involving pharmaceuticals. While not a therapeutic agent, CFPAT-1 functions as a regulatory scaffold that flags drug procurement, formulary manipulation, and referral-linked prescribing patterns. It integrates validator ballots, smart contract logic, and SHA-256 hash anchors to escalate complaints to CMS, DOJ, and state boards. All flagged drugs are traced via QR-linked audit trails and NFT fiscal declarations. No biospecimens are retained; the intervention operates within legal, technical, and governance domains.

Sponsors

Truway Health, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Facility has documented billing, compliance, or procurement irregularities. Facility participates in coalition validator onboarding and SHA-256 protocol enrollment. Facility provides access to billing, procurement, and whistleblower-anchored datasets for auditing.

Exclusion criteria

Facility refuses validator onboarding or coalition integration. Facility lacks traceable procurement or compliance records. Facility has no whistleblower declaration or validation artifact. Facility operates outside U.S. jurisdiction or coalition-recognized governance zones.

Design outcomes

Primary

MeasureTime frameDescription
Change in Fraudulent Billing and Kickback Incidents Across Enrolled FacilitiesBaseline to 12 Months Post-Validator OnboardingDescription: This outcome measures the change in frequency and severity of fraudulent billing practices-including upcoding, phantom billing, and referral-based kickback schemes-across facilities enrolled in the SHA-256 Trial Protocols. Facilities are assessed using the Unified Impact Index derived from: Historical billing anomalies Validator audit results Whistleblower declarations SHA-256 hash-anchored incident reports Facilities are ranked and monitored for reform compliance, ethical standards, and onboarding validation. All scoring logic is notarized and displayed via coalition dashboards. Time Frame: Baseline to 12 Months Post-Validator Onboarding.

Secondary

MeasureTime frameDescription
Change in Supply-Chain Traceability and Compliance Across Enrolled FacilitiesBaseline to 12 Months Post-Validator OnboardingThis outcome measures change in traceability and regulatory compliance for pharmaceuticals, medical devices, and non-pharmaceutical supplies. Facilities are evaluated using: Validator Traceability Score (VTS) composite metrics NFT tagging for supply-chain nodes Blockchain-based audit trails Comparative analysis dashboards identifying gaps and escalation pathways for non-compliant entities

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026